Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
- C -R Pradeep 1,2, A Zeisel 3, W J Köstler 1,4, M Lauriola 1, J Jacob-Hirsch 5, B Haibe-Kains 6,7, N Amariglio 5, N Ben-Chetrit 1, A Emde 1, I Solomonov 8, G Neufeld 9, M Piccart 6, I Sagi 8, C Sotiriou 6, G Rechavi 5, E Domany 3, C Desmedt 6, Y Yarden 10
- C -R Pradeep 1,2, A Zeisel 3, W J Köstler 1,4
- 1Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
- 2Department of Systems Biology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
- 3Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
- 4Clinical Division of Oncology, Department of Medicine 1 and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 5Department of Pediatric Hemato-Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- 6Institut Jules Bordet, Translational Research Unit, Brussels, Belgium.
- 7Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium.
- 8Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
- 9Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
- 10Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. yosef.yarden@weizmann.ac.il.
- 0Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

